JP2009538935A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538935A5
JP2009538935A5 JP2009513472A JP2009513472A JP2009538935A5 JP 2009538935 A5 JP2009538935 A5 JP 2009538935A5 JP 2009513472 A JP2009513472 A JP 2009513472A JP 2009513472 A JP2009513472 A JP 2009513472A JP 2009538935 A5 JP2009538935 A5 JP 2009538935A5
Authority
JP
Japan
Prior art keywords
myxoma virus
activity
group
cancer
myxoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009513472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/070219 external-priority patent/WO2007143548A2/en
Publication of JP2009538935A publication Critical patent/JP2009538935A/ja
Publication of JP2009538935A5 publication Critical patent/JP2009538935A5/ja
Withdrawn legal-status Critical Current

Links

JP2009513472A 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体 Withdrawn JP2009538935A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80364006P 2006-06-01 2006-06-01
PCT/US2007/070219 WO2007143548A2 (en) 2006-06-01 2007-06-01 Myxoma virus mutants for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013040387A Division JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体

Publications (2)

Publication Number Publication Date
JP2009538935A JP2009538935A (ja) 2009-11-12
JP2009538935A5 true JP2009538935A5 (enExample) 2010-07-08

Family

ID=38802246

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009513472A Withdrawn JP2009538935A (ja) 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体
JP2013040387A Expired - Fee Related JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体
JP2014248831A Pending JP2015044878A (ja) 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体
JP2016197808A Pending JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013040387A Expired - Fee Related JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体
JP2014248831A Pending JP2015044878A (ja) 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体
JP2016197808A Pending JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Country Status (12)

Country Link
US (3) US8512713B2 (enExample)
EP (3) EP3254694A1 (enExample)
JP (4) JP2009538935A (enExample)
KR (1) KR20090014364A (enExample)
CN (1) CN101460194B (enExample)
AU (1) AU2007256754B2 (enExample)
CA (2) CA2951453A1 (enExample)
IL (1) IL195297A (enExample)
MX (1) MX2008015265A (enExample)
NZ (1) NZ572893A (enExample)
WO (1) WO2007143548A2 (enExample)
ZA (1) ZA200809769B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512713B2 (en) 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
FR2946536B1 (fr) 2009-06-11 2011-07-29 Agronomique Inst Nat Rech Utilisation d'une souche attenuee de myxoma virus comme oncolytique
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
US12428626B2 (en) 2018-11-20 2025-09-30 Bioventures, Llc Cells for the production of viruses and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
WO2001087324A1 (en) 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
BR0207761A (pt) * 2001-03-08 2006-01-31 Akzo Nobel Nv Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo
WO2004078206A1 (en) 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
DK2388315T3 (da) * 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US8512713B2 (en) 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments
WO2007147118A1 (en) 2006-06-16 2007-12-21 Robarts Research Institute Infection of cells with myxoma virus requires akt activation

Similar Documents

Publication Publication Date Title
He et al. Oxidative stress, inflammation, and autophagy: potential targets of mesenchymal stem cells-based therapies in ischemic stroke
Geng et al. Biomimetic nanovehicle-enabled targeted depletion of intratumoral Fusobacterium nucleatum synergizes with PD-L1 blockade against breast cancer
Bloy et al. Trial Watch: Radioimmunotherapy for oncological indications
JP6505681B2 (ja) Flt3変異を有する急性骨髄性白血病を治療するための医薬組成物
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
EP1385466A4 (en) ONCOLYTIC VIRUS THERAPY
CN112007163B (zh) 用于治疗非洲猪瘟的药物组合物及其用途
CN104884055A (zh) 柠檬酸铁在治疗慢性肾脏疾病患者中的应用
JP2011225596A5 (enExample)
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
JP2018509388A5 (enExample)
Li et al. Cationic poly (amidoamine) dendrimers induced cyto-protective autophagy in hepatocellular carcinoma cells
JP2012107063A5 (enExample)
JP2006516571A5 (enExample)
SE0950390L (sv) System och process för tillverkning av en lösning med suspenderade fasta ämnen och användningar därför
Elias et al. L-arginine as an adjuvant drug in the treatment of sickle cell anaemia.
JP5718639B2 (ja) 電離放射線誘発の損傷から哺乳類細胞を保護する方法
JP5665899B2 (ja) 癌の処置のための粘液腫ウイルス変異体
Zhu et al. Cysteine metabolism reprogramming-motivated catalytic immunotherapy for orthopedic biofilm infections
Li et al. Novel multifunctional Zn-MOF for synergistic inhibition of coronaviruses
MX367580B (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.
CN101711758A (zh) 芹菜素在制备预防和治疗人缺血损伤引起疾病的药物应用
Xie et al. From stem cells to nanomedicine: A multimodal approach targeting pancreatic fibrosis via MFGE8-dependent ANXA1-SMAD2/3 axis
TR200201654T2 (tr) Benzamidin türevleri.
JP2004529158A5 (enExample)